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Environmental novelty exacerbates 
stress hormones and Aβ pathology 
in an Alzheimer’s model
Kimberley E. Stuart  1, Anna E. King1, Carmen M. Fernandez-Martos1, Mathew J. Summers  2 
& James C. Vickers1
Cognitive stimulation has been proposed as a non-pharmacological intervention to be used in 
primary, secondary and tertiary prevention approaches for Alzheimer’s disease. A common familial 
Alzheimer’s disease transgenic model showed heightened levels of the stress hormone, corticosterone. 
When exposed to periodic enhanced cognitive stimulation, these animals demonstrated further 
heightened levels of corticosterone as well as increased Aβ pathology. Hence, Alzheimer’s disease 
may be associated with hypothalamic-pituitary-adrenal (HPA) axis dysfunction, causing stimulatory 
environments to become stress-inducing, leading to a glucocorticoid-pathology cycle contributing to 
further Aβ release and plaque formation. This finding suggests that stimulation-based interventions 
and local environments for people with Alzheimer’s disease need to be designed to minimise a stress 
response that may exacerbate brain pathology.
The ageing of the global population is accompanied by an increasing substantial social and financial impact of 
ageing-related diseases that cause dementia. Among elderly populations, Alzheimer’s disease (AD) is the most 
common cause of dementia1. Research has consistently demonstrated that the environment influences the brain 
both structurally and functionally over the lifetime2. In this respect, among modifiable factors that are associated 
with a reduced risk of developing dementia, is living a cognitively engaged life. Indeed, those who engage in high 
levels of cognitive activity have approximately half the risk of developing dementia than those who engage in low 
levels3. The cognitive reserve theory (CR) posits that a high-level of intellectual engagement over the life promotes 
strong and efficient neuronal connections that enables the neural system capacity to withstand a greater degree of 
pathological insult before clinical expression of the disease process emerges4.
In animal models, the building of cognitive reserve can be modelled experimentally through an environmen-
tal enrichment (EE) paradigm. EE describes the manipulation of an animals’ environment in order to generate 
novelty and complexity, and heighten cognitive, sensory, and physical stimulation5. EE applied in early-life has 
been found to boost cognitive performance in familial AD (FAD) transgenic mouse models to the level of healthy 
wildtypes (Wt). However, EE is reported to have a variable effect on Aβ pathological burden in transgenic mice 
expressing human FAD-related gene mutations, with reported decrease6–8, no change9–11, or increase12, 13 in Aβ 
load. Alternatively, it is possible that more complex, and novel stimulation may be required to buffer AD-related 
neuropathology3. Further, individuals are more likely to take up interventions to delay dementia onset in mid- 
to late-life, or even after the onset of early symptoms of dementia. In a previous investigation, we demonstrated 
some beneficial effects of mid-life EE on cognitive function, with no changes to Aβ neuropathological burden in 
FAD model mice14. Therefore, we sought to examine whether added periodic augmentation of more novel stim-
ulation (EE+) in FAD animals from mid-life (6 months of age), would produce findings consistent with previous 
reports of reduced Aβ burden following EE6–8. In order to examine EE in mid to later-life, mice were raised in 
standard housing (minimal stimulation; SH) conditions until 6 months of age, and then randomly assigned to SH, 
environmental enrichment (EE) or enhanced environmental enrichment (EE+) conditions, where the animals 
remained until 12 months of age. Mice in EE lived in a larger cage to that of SH, and enrichment objects were 
present in the cage (wooden and plastic blocks of differing shapes and sizes, platforms, a ball, running wheel, and 
a mouse hut). Mice in the EE+ condition lived in EE, but were also exposed to a novel, larger cage three times per 
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week that contained novel enrichment objects (e.g. steps, ladders, large running wheel, mazes, toys of different 
textures; changed weekly).
Results
Mid-life EE+ was associated with increased Aβ plaque pathology in the hippocampus. 
Following the 6-month intervention, when mice were 12 months of age, we hypothesised exposure to the EE+ 
intervention would potentially be associated with a reduction in Aβ plaque burden. We analysed fibrillar plaque 
load by Thioflavin-s (Fig. 1E) staining and by immunostaining of human unagreggated, oligomeric, and fibrillar 
forms of Aβ1-42 with the MOAB-2 antibody (Fig. 1F), in the neocortex and hippocampus of APP/PS1 mice. No 
significant alterations to Aβ load in the neocortex as a function of housing condition was detected for either 
Thioflavin-s or MOAB-2 labelled Aβ plaques (Fig. 1A,C). In contrast, there was a large (d = 1.08) and significant 
increase in hippocampal fibrillar Aβ plaque load in APP/PS1 mice exposed to the EE+ condition (Fig. 1B), and 
this effect was also detected for Aβ1-42 immunolabelling (Fig. 1D; d = 1.83).
Mid-life EE+ was associated with increased Aβ1-42 in neocortex. Next, we examined levels of sol-
uble Aβ1-42 in the neocortex and hippocampus, and found an overall significant effect of housing condition on 
Aβ1-42. APP/PS1 mice housed in EE+ showed a large (d = 1.89) and significant increase in Aβ1-42 in neocortex, 
compared to mice from SH or EE (Fig. 2A). However, in contrast to the finding of an increase in Aβ plaque depo-
sition in the hippocampus, this effect was not observed for Aβ1-42 levels in the hippocampus (Fig. 2B). These data 
suggest that EE+ is associated with increases in Aβ levels in the neocortex, and increased deposition of Aβ in the 
hippocampus.
APP/PS1 mice demonstrated elevated levels of corticosterone. While our assumption had been 
that placing animals in an enhanced EE condition may have augmented cognitive and physical stimulation, it was 
also possible that this exposure had broader physiological effects that may have led to increased Aβ pathology, 
and that the FAD background also contributed to an unexpected reaction to the EE+ condition. Previous clinical 
studies have reported that people living with AD generally have higher blood-levels of the stress hormone, corti-
sol, when compared to healthy people15, 16. However, whether the disease process itself alters normal stress phys-
iology, or whether stress increases vulnerability to developing AD, is unknown. It is widely accepted that stress 
induces activation of the hypothalamic-pituitary-adrenocortical (HPA) axis, which leads to a subsequent release 
of cortisol in humans, or corticosterone in rodents, from the adrenal cortex17, 18. Several studies, using experimen-
tal paradigms designed to induce stress, have demonstrated an accelerated onset, or faster rate of progression of 
AD, in FAD mouse models19–23. Such evidence led us to hypothesise that the novelty and complexity conferred by 
the EE+ condition, elevated stress levels, which may in turn have increased Aβ pathological burden in APP/PS1 
mice in EE+ housing. We first compared levels of the stress hormone, corticosterone, between healthy control 
Wt and APP/PS1 mice from the SH condition, in order to determine whether the presence of the APP/PS1 trans-
gene was associated with elevated corticosterone. Corticosterone levels in serum were significantly increased in 
12-month old APP/PS1 mice compared to healthy Wt mice, which represented a large effect (d = 1.09) (Fig. 3). 
This finding supports the hypothesis of HPA axis dysfunction in AD.
Mid-life EE+ was associated with elevated corticosterone levels in APP/PS1 mice. Following 
the finding of elevated levels of corticosterone in APP/PS1 mice compared to Wt mice from SH, we included EE 
and EE+ conditions into the analysis. First, we found an overall significant interaction effect of genotype x hous-
ing on corticosterone levels. Due to the APP/PS1 mice demonstrating increased corticosterone levels, we analysed 
genotypes separately to investigate housing effects. In Wt mice, there was no significant housing condition effect 
on corticosterone levels. However, there was a significant and large effect of housing condition for APP/PS1 mice. 
While the APP/PS1 mice from SH exhibited increased corticosterone levels relative to Wts, APP/PS1 mice from 
EE+ showed further elevated corticosterone levels, being significantly higher compared to APP/PS1 mice from 
both the SH and EE conditions (d = 1.05) (Fig. 3).
Discussion
Our study has shown that periodic augmentation of EE conditions in APP/PS1 mice may have a deleterious effect 
on Aβ pathology, and this was associated with heightened levels of corticosterone, in a FAD model that already 
showed elevated stress hormone levels over Wt animals of a similar age. In contrast, sustained exposure to regular 
EE conditions did not affect corticosterone levels or amyloid pathology, indicating a potential capacity to habitu-
ate to long-term changes in the housing environment. While APP/PS1 animals housed in EE+ had increased Aβ 
pathology along with elevated corticosterone, no significant behavioural differences were detected on the Y maze 
test of spatial short-term memory, or the Barnes maze test of spatial learning and long-term memory relative to 
APP/PS1 mice housed in SH or EE (data not shown). The finding of increased pathological burden without cog-
nitive dysfunction may offer support for the cognitive reserve theory4, however following up at later time points 
when neural resources are reduced, would be of interest.
Clinical studies have included reports of people living with AD to generally have higher levels of blood cortisol 
when compared to healthy people15, 16. Moreover, elevated levels of corticosterone has been reported previously in 
a FAD mouse model24, and Aβ accumulation has been associated with increased sensitivity of the HPA axis23. The 
present study confirms HPA axis dysfunction in an animal model of early AD. Several studies have demonstrated 
using experimental paradigms designed to induce acute stress (e.g. by restraint, loud noise, and bright light) an 
accelerated onset, or faster rate of progression of AD, in FAD mouse models19–23. However, in the current report, 
we found an association between the periodic stimulation condition and increased corticosterone. APP/PS1 mice 
display Aβ pathology from 4-5 months of age25, in the hippocampus and neocortex, and associated damage to 
synapses26, and the hippocampus directly regulates the HPA axis27–29. Green and colleagues30 speculated that, 
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in AD, glucocorticoid feedback to the hippocampus may be lost, leading to an increased stress response. The 
increasing levels of glucocorticoid may further accelerate pathological processes, acting as a cycle of disease pro-
cess progression. Notably, Wt mice did not show increased corticosterone levels after exposure to EE+, and, thus, 
were not stressed by the periodic stimulation of the EE+ condition. In contrast, FAD gene-linked deposition 
Figure 1. Aβ plaque load in neocortex and hippocampus in APP/PS1 mice exposed to differential housing. (A) 
Thioflavin-S staining of fibrillar and dense core Aβ plaques demonstrated no significant difference in plaque 
load in neocortex between the housing groups, F(2, 19) = 0.78, p = 0.47. (B) A significant effect of housing was 
detected on Thioflavin-s plaque load in the hippocampus, F(2, 19) = 4.80, p = 0.02. Bonferroni adjusted post 
hoc tests revealed APP/PS1 mice housed in EE+ had higher hippocampal Aβ fibrillar plaque burden when 
compared to those in SH (p = 0.02). (C) MOAB-2 immunolabelling demonstrated no significant differences 
across housing groups in Aβ1-42 load, F(2, 18) = 0.65, p = 0.54. (D) A significant effect of housing condition was 
detected on hippocampal MOAB-2 load, F(2, 18) = 7.78, p = 0.005. Bonferroni adjusted post hoc tests showed EE+ 
mice to have a significantly higher hippocampal MOAB-2 load relative to mice in SH. SH (n = 9), EE (n = 7), 
EE+ (n = 6) *p < 0.05, **p < 0.01, ***p < 0.001. (E) Representative 10x Thioflavin-s staining in hippocampus 
of APP/PS1 mice for each housing group. (F) Representative 10x MOAB-2 staining in hippocampus of APP/PS1 
mice for each housing group.
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of Aβ in the hippocampus and synaptic damage in transgenic animals may lead to initial dysregulation of the 
HPA-axis, which contributed to a heightened stress response following periodic stimulation in the EE+ condi-
tion. Whereby, this periodic stimulation in EE+ may stimulate a harmful cascade, with subsequent increases in 
Aβ leading into an increased stress response to EE+, further increasing circulating corticosterone, and further 
Aβ deposition within the hippocampus.
The finding that elderly who enter a nursing home demonstrate more rapid cognitive decline compared to 
those who remain in the community31, together with the findings of this study, raise questions into the effect 
of novel environments for people with AD on disease progression. Moreover, the findings presented here bring 
into question cognitive interventions for the elderly, and for people living with AD in particular. An interven-
tion aimed at delaying the progression of the clinical syndrome, dementia, is urgently needed given the rap-
idly increasing ageing population. As there are no current efficacious pharmacological treatments available, 
non-pharmacological interventions such as cognitive stimulation, training, and rehabilitation are of current 
interest. Such interventions have demonstrated various levels of efficacy, although modest sized effects are typi-
cally reported32. To our knowledge, the effects of cognitive intervention on stress in people living with AD has not 
been examined. Moving forward, this will be an important point of investigation, as cognitive interventions for 
Figure 2. Aβ1-42 levels in neocortex and hippocampus in APP/PS1 mice across differential housing conditions. 
(A) Overall, there was a significant effect of housing condition on cortical Aβ1-42 levels, F(2, 12) = 10.41, p = 0.002. 
Follow-up post-hoc tests were performed with Bonferroni correction applied. The EE+ group had significantly 
higher cortical Aβ1-42 compared with both SH (p = 0.003) and EE (p = 0.012). (B) No significant differences 
were detected in hippocampal Aβ1-42 levels between housing conditions, F(2, 12) = 0.04, p = 0.96. SH (n = 5), EE 
(n = 5), EE+ (n = 5) *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 3. Differential corticosterone levels according to genotype and housing condition. APP/PS1 mice in 
SH had significantly higher levels of corticosterone in blood serum compared to healthy Wt control mice at 
12 months, t(24) = 2.34, p = 0.03. There was a significant interaction effect of genotype × housing on levels of 
corticosterone, F(2, 66) = 3.76, p = 0.03. In Wt mice, there was no significant effect of housing on corticosterone, 
F(2, 28) = 0.31, p = 0.74. Housing condition produced a significant effect on corticosterone levels in APP/PS1 
mice, F(2, 38) = 4.8, p = 0.01. Bonferroni adjusted post hoc tests revealed EE+ mice had significantly higher 
corticosterone levels compared to SH (p = 0.02). Moreover, EE+ mice had higher corticosterone levels than 
mice housed in EE (p = 0.049), however, this was no longer significant when Bonferroni correction was applied 
(p = 0.057). SH Wt (n = 9), EE Wt (n = 12), EE+ Wt (n = 10); SH Tg (n = 17), EE Tg (n = 12), EE+ Tg (n = 12)  
*p < 0.05, **p < 0.01, ***p < 0.001.
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people living with AD may have limited beneficial effect, and may potentially induce stress leading to an increased 
progression of disease processes. Likewise, given that Aβ pathology may be present in the brain many years before 
overt dementia symptomology33, it will be important to examine the role that stress may have in facilitating 
further pathology, and that primary and secondary prevention strategies that involve cognitive stimulation are 
designed to minimise elevated stress.
Methods
Animals and EE protocol. In the current study, we used a transgenic mouse model of AD that most closely 
resembles early-stage AD26. Male mice expressing chimeric mouse/human amyloid precursor protein (APP) and 
mutant human presenilin 1(PS1) on C57BL/6 background [B6.Cg-Tg (APPswe, PSEN1dE9) 85Dbo/J] (APP/PS1; 
Jankowsky et al.25 and littermate wildtype (Wt) control mice were housed in standard housing (SH) conditions 
(4-5 mice per 30 × 30 × 14 cm cage, ad libitum access to food and water, an igloo, one small wooden stick and one 
tissue) until 6 months of age. At 6 months, mice were randomly assigned to SH, EE, or EE+ conditions for the 
following 6 months. Mice assigned to the EE and EE+ housing conditions lived in a larger 60 × 30 × 14 cm cage 
with the contents of the SH cage and the addition of enrichment objects (wooden and plastic blocks of differing 
shapes and sizes, platforms, a ball, running wheel, and a mouse hut). The EE+ condition involved the mice being 
exposed to a larger (36 × 49 × 22 cm) cage three times per week that contained novel enrichment objects (changed 
weekly). Housing conditions were maintained until the 12-month end-point. All experimental procedures pre-
sented here were performed in accordance with the Australian Code of Practice for the Care and Use of Animals 
for Scientific Purposes, and approved by the University of Tasmania Animal Ethics Committee (A13253).
Tissue collection. Mice were terminally anaesthetized first with gas anaesthesia (isoflurane) followed by 
sodium pentobarbitone (100 mg/kg delivered intraperitoneally). For histological analysis, animals were perfused 
transcardially with 4% paraformaldehyde (PFA) in 0.1 M phosphate buffered saline (PBS pH 7.4). Post-mortem 
brains were transferred to 18% then 30% sucrose solutions overnight. Brains were cut on a cryostat (Leica CM 
1850) in 40 μm coronal sections. APP/PS1 mice used for the quantification of human soluble Aβ42, were termi-
nally anaesthetized as above, and perfused transcardially with PBS (0.1 M). Post-mortem brains were removed 
and the cortex and hippocampus were dissected and immediately frozen in liquid nitrogen. Cortex and hip-
pocampal samples were stored at −80 °C for later analysis.
Aβ fibrillar plaque deposition. Thioflavin-S (Sigma-Aldrich) staining was performed in order to visualise 
fibrillar and dense-core Aβ plaques34, ten serial sections evenly spaced throughout the rostrocaudal axis of the 
brain from bregma 2.0–3.0 mm according to the stereotaxic mouse brain atlas35 were incubated in the solution 
(0.125% Thioflavine-S diluted in 60% absolute ethanol with 40% 0.01 M PBS) for 3 minutes at room temperature, 
and washed for 2 × 1 minute in 50% absolute ethanol and 50% 0.01 M PBS solution, followed by 3 × 10 minute 
washes in 0.01 M PBS. MOAB-2 immunostaining was performed in order to visualize human fibrillar, as well as 
unaggregated and oligomeric forms of Aβ4214, 36. Ten serial sections evenly spaced throughout the rostrocaudal 
axis of the brain from bregma 2.0–3.0 mm were immunolabelled with the MOAB-2 antibody (1:2000; Novus 
Biologicals), and the labelling was visualized by inclubation in Alexa-fluorophore conjugated secondary antibody 
(1:1000; Molecular Probes, goat anti-mouse IgG2b-546). Sections were mounted using Dako fluorescent mount-
ing medium.
Image acquisition. In order to determine Aβ plaque load in the neocortex and hippocampus, images were 
taken on a Leica DM fluorescence microscope on a 10x objective with NIS Elements imaging software. The left 
side of the cortex was imaged from the midline to the rhinal fissure from bregma 2.0–3.0 mm of 10 sections per 
animal. Images of the whole hippocampal formation were taken between bregma position −1.22 and −2.46 mm 
of 3–5 sections per animal. Aβ plaque load (percentage area Thioflavin-S positive) was calculated by random for-
est segmentation for one hemisphere of the neocortex and the whole hippocampal formation. Whereby, a custom 
plugin for ImageJ was applied to the images, which automatically segmented images as plaques or background 
pixels by random forest classification37. The percent area stained by Thioflavin-S in the neocortex and hippocam-
pus was calculated by dividing the labelled area by the total area analysed.
Aβ42 ELISA. For the quantitation of human Aβ1-42, a sandwich antibody ELISA was performed according to 
the manufacturer’s instructions (KHB3441, Invitrogen). The right side of the neocortex and hippocampus were 
homogenized in RIPA buffer (Sigma) containing a protease (Roche diagnostics) and phosphatase inhibitor cock-
tail (AG Scientific). The samples were centrifuged for 15 minutes at 13000 RPM, rotated for a further 30 minutes, 
and centrifuged again at 4 °C for 15 minutes at 13000 RPM. The resulting supernatant was removed and stored 
at −80 °C for protein analysis. The protein concentrations of samples were determined using the Bradford assay. 
Duplicate neocortex and hippocampus samples from APP/PS1 mice (n = 5/group) were diluted in the buffer 
provided (1:50). Soluble human Aβ1-42 levels were normalized to total protein levels and expressed as picogram 
of Aβ1-42 content per milligram of total protein (pg/mg). Optical densities were read at 450 nm on a microplate 
reader (SpectraMax, Molecular Devices), and concentrations of Aβ1-42 were determined by comparison to the 
standard curve using a 4-parameter algorithm.
Corticosterone ELISA. In order to determine if there were differences in levels of stress between the hous-
ing conditions and genotypes, blood was collected at time of perfusion by cardiac puncture, performed at the start 
of the dark period (3 p.m.). Duplicate serum samples were diluted at 1:100 in the buffer provided, and levels of 
serum corticosterone were measured by a commercial ELISA kit (ab108821; Abcam) according to manufacturer 
instructions. Optical densities were read at 450 nm on a microplate reader (SpectraMax, Molecular Devices), 
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and concentrations of corticosterone were determined by comparison to the standard curve using a 4-parameter 
algorithm.
Statistical analysis. Statistical analyses were performed using independent t-test and two-way ANOVA 
using IBM SPSS (Version 20). A statistically significant two-way ANOVA was followed up by post hoc tests. 
Variables considered were genotype (Wt or Tg) and housing condition (SH, EE, or EE+). Values of p < 0.05 for 
differences between group means were classified as statistically significant. The magnitude of differences between 
the means were reported as Cohen’s d.
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
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